Indeed, approximately 5% of individuals with T2DM experience hypoglycaemia within 6 months of initiation of insulin therapy.58 When hypoglycaemia occurs soon after insulin therapy is commenced, individuals are more likely to discontinue BI therapy within the first 12 months (hazard ratio, 1.16; 95% CI, 1.03, 1.32; P = .016).58 Although no studies are available for direct illustration, reducing hypoglycaemia risk during the titration period, when most dose adjustments are made, may potentially improve and facilitate adherence to, and persistence with, the regimen. Here, INS is linked to Hypoglycemia.